We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4XD.L Regulatory News (C4XD)

  • There is currently no data for C4XD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

19 Nov 2019 07:00

RNS Number : 8196T
C4X Discovery Holdings PLC
19 November 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

C4X Discovery Holdings Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Rights Issue & Equity Offering

X

3. Details of person subject to the notification obligationiv

Name

Polar Capital LLP

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

15/11/2019

6. Date on which issuer notified (DD/MM/YYYY):

18/11/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

10.13%

10.13%

108,366,444

Position of previous notification (if

applicable)

9.61%

9.61%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BQQ2RV18

10,978,188

10.13%

SUBTOTAL 8. A

10,978,188

10.13%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Polar Capital Holdings PLC

%

%

%

Polar Partners Ltd

%

%

%

Polar Capital LLP

10.13%

10.13%

10.13%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, UK

Date of completion

18/11/2019

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLCKFDNBBDBADD
Date   Source Headline
14th Mar 20177:00 amRNSProposed Placing to raise up to £7.0 million
9th Feb 20177:00 amRNSChange of Adviser
2nd Feb 20177:00 amRNSGRANT OF OPTIONS AND DIRECTORS DEALING
31st Jan 20171:06 pmRNSResult of AGM
6th Jan 20177:00 amRNSFull year results for the year ended 31 July 2016
19th Dec 20167:00 amRNSNotice of Results
30th Nov 20162:25 pmRNSDirector/PDMR Shareholding
24th Nov 20167:00 amRNSGRANT OF OPTIONS AND DIRECTORS DEALING
22nd Nov 20167:00 amRNSBoard Changes
30th Sep 20167:00 amRNSHolding(s) in Company
28th Sep 201610:41 amRNSHolding(s) in Company
28th Sep 20167:00 amRNSC4X Enters New Collaboration with Evotec
26th Sep 201611:53 amRNSResult of General Meeting
6th Sep 20167:00 amRNSC4X Discovery £5 Million Fundraise
12th Jul 20167:00 amRNSAcquisition of drug-discovery technologies
4th Jul 20167:00 amRNSNew drug targets identified for development
4th May 20167:00 amRNSAppointment of Clive Dix as CEO
28th Apr 20163:58 pmRNSHolding(s) in Company
28th Apr 20163:57 pmRNSHolding(s) in Company
26th Apr 20167:00 amRNSGrant of options
17th Mar 20167:00 amRNSInterim Results
15th Mar 201610:00 amRNSNotice of Interim Results
1st Mar 20167:00 amRNSAcquisition of Genetic Analysis Company
9th Dec 20157:00 amRNSDirector/PDMR Shareholding
8th Dec 20152:43 pmRNSResult of AGM
19th Nov 20157:00 amRNSAppointment of Exec Chairman and departure of CEO
29th Oct 20157:00 amRNSDirector/PDMR Shareholding
28th Oct 20157:00 amRNSPreliminary Results
28th Oct 20157:00 amRNSCollaboration with the SGC
7th Oct 20157:00 amRNSResearch update: IL-17
23rd Sep 20157:00 amRNSResearch update: Breakthrough compounds
3rd Sep 20157:00 amRNSSenior Management and Biology Hires
9th Jun 20152:00 pmRNSGrant of Options
20th May 20157:00 amRNSPre-clinical development of drug candidate
27th Apr 20157:00 amRNSInterim Results
21st Apr 20153:05 pmRNSNotice of Results
10th Apr 20153:10 pmRNSChange of Registered Office
10th Apr 20151:34 pmRNSChange of Registered Office
20th Feb 20154:45 pmRNSHolding(s) in Company
19th Jan 20157:00 amRNSC4X enters into new research agreement with Evotec
18th Dec 20147:00 amRNSC4X Discovery renews collaboration with Evotec AG
24th Oct 20143:37 pmRNSHolding(s) in Company
23rd Oct 20144:38 pmRNSTR-1: Notification of Major Interest in Shares
23rd Oct 20143:00 pmRNSTR-1: Notification of Major Interest in Shares
23rd Oct 20147:00 amRNSFirst Day of Dealings on AIM after £11m Placing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.